Byotrol Share Discussion Threads

[1gw] 25/1/2021 11:14

Thanks for that ghost. Original announcement in August 2015 talked about initial focus on EU consumer, but with expectation to expand scope:

"Initially Byotrol will pool technical, commercial and sales resource with Solvay Novecare in targeting Products at the EU consumer market. Over time we expect to be expanding into other geographies, into professional markets and in due course into personal care markets too. The two parties will then be sharing gross profit from any jointly-developed products."
...
'Thierry Sclapari, Global Vice President, Home and Personal Care, Solvay Novecare commented: "We see a big opportunity for our unique polymer technologies in Byotrol's anti-microbial systems. We look forward to taking our jointly-developed products to our customers worldwide.'


The extract below from the 2016 annual report suggests that the scope had by then explicitly become worldwide for consumer and also included some professional markets

"Following the subsequent deal expansion, Byotrol is now pooling technical, commercial and sales resource with Solvay Novecare in targeting products at the worldwide consumer market and some professional markets."

So it would be logical to assume that byotrol's rights to royalty/commission (and usage rights) from the subsequent sale of IP to Solvay would be worldwide.

[the ghost who walks] 25/1/2021 10:44

The original agreement with solvay was for eu product launch, I believe, at least that's what the 2015 announcement said. They then subsequently updated this agreement and it didn't mention geography.

[1gw] 25/1/2021 09:50

That's the question ghost. Unfortunately, I don't think byotrol can tell us the key numbers (royalty/commission %) on Solvay and IRI for confidentiality reasons, so we probably have to wait to see meaningful royalty payments start to flow through the accounts.

You might expect finnCap as house broker to have a better feel than most, but even they are in the dark I suspect. Initially (April 2018) they estimated the Solvay royalty as being in the 3% to 5% range, and in December 2018 went for "low to mid-single digit range" although in the latest note they appeared to plump for 5%.

Looking back over the finnCap notes, I realise why they tend to talk about market for Solvay excluding the US. In December 2018 they made the comment "IP and marketing (ex-US) were sold to Solvay". I think this has to be a mistake, as byotrol have not said anything about a geographic limitation on the Solvay sale as far as I am aware and Solvay are clearly gearing up for a US Actizone business. So might we expect to see finnCap up their estimates for Solvay royalty if they increase the addressable market to include the US?

[the ghost who walks] 25/1/2021 09:14

That's backward looking, can the run rate grow to 5mln over the next few years as Slovay launches and the us takes off?

[tradertrev] 25/1/2021 09:01

My daughter lives in Malaysia and showed me a bottle of Wizact24 she had just bought online over there, after I'd mentioned it. It's freely available now, though she hasn't seen it in any shops yet. It has a very nice citrus aroma and I hope she'll be recommending it to friends.

[football] 24/1/2021 20:21

STT can you stop spamming the thread with the same postsYou really must have some medical condition that you are spending all your time repeating the same stuff 24/7 365 days of the year when you don't hold any shares in Byotrol.Go and get a life or at least get layed

[sikhthetech] 24/1/2021 19:39

The ghost,

Royalty/licensing income was only £780k last year and only £590k for H1, which was during the initial surge of covid. Now more and more organisations/companies will enter the market and with vaccine rollout and a better understanding of the virus, the need for hand sanitisers/cleaning products would decrease


Professional Royalty & Licensing:

Let's have a read of their accounts...
Royalty income:
fy2020 £780k,
H1 2021 £590k



Other organisations/companies entering the market:

Look at Virusend. Within a few months, developed, tested, BS marks and already in the shops.
Developed in conjunction with the British Army and used by them across testing centres around the UK.


according to Virusend - is this true, It's the only disinfectant available for home users that is full spectrum bactericide?:

"A breakthrough innovation, VIRUSEND is currently the only disinfectant available to home consumers that is a full spectrum bactericide and proven to eliminate the human strain SARS-CoV-2 Coronavirus (Covid-19 virus). Tested to the stringent BSEN:16777 standard, and developed in conjunction with the British Army (who already use it), this military-standard spray will kill Coronavirus in one minute. Or, to put it in plain English, this clever bottle is what you need at home to zap Coronavirus in 60 seconds flat."

[the ghost who walks] 24/1/2021 18:16

If the royalty income can get to 5mln, that would be worth 50-100mln alone, then the rest at say another 100mln. That's my bluesky

[sikhthetech] 24/1/2021 14:38

Riddleone
"All they need to do now is get the traffic through the sites which is obviously the hardest part."

They need advertising.


This year, ending in 2 months, March, their royalty and licensing income isn't going to cover the reduced demand from consumer division.
Last year, there was a monthly update with, record sales/selling as much as they can make/£1m per month order... Currently there's nothing similar so suggests orders are down.


Facts from their H1-2021 accounts published Dec. Rest is jam tomorrow.


£590k (yes k) increase in global consumer sales during H1 (Apr-Sept) when there's the biggest pandemic to hit the globe is not impressive.


So with the biggest pandemic to strike in a century they managed £997k (ex-royalty & licensing) of consumer sales!
That includes Boots, Homeandcleaning, direct website sales, global sales.




Consumer:

"H1 revenues more than doubled to £1.01m from £0.41m, including a small amount of IP-based income, versus nil IP income in the comparable period. Gross profit (on products) increased to £0.43m from £0.17m. "
"Elsewhere, sales across existing customers all increased in this segment, especially into Japan via our longstanding agents in pet and healthcare."



Professional Royalty & Licensing:


Let's have a read of their accounts...
Royalty income:
fy2020 £780k,
H1 2021 £590k


FY2020:

"We also recognised revenue and gross profit from IP agreements of £0.78m, lower than the prior year (which benefited from one large IP agreement with Solvay SA)."




H1 2021:
"including £0.59m of royalty and licensing revenue"

Royalty & Licensing income £591k (yes k)

See Segmental analysis




Read the results, it's all there in black and white.
£31m mcap - really!! - that's a huge amount of jam tomorrow.

[football] 24/1/2021 13:20

They are doing cars but what about planes next?

[the ghost who walks] 24/1/2021 08:31

Agree. What i find tricky is to size the two options, plus the seaweed thing. Could this be a 100mln mcap. Business?

[1gw] 23/1/2021 10:37

One possibility that I think this might open up is byotrol selling Actizone into the US once EPA approvals have been obtained by Solvay.

Byotrol has given IRI a 10-year exclusive licence for byotrol24, and if IRI is successful and gets the byotrol brand established in the US over the next year or two, byotrol could look to leverage that by launching a byotrol Actizone product. At that point, byotrol should be a much stronger company than it was when it was looking for a partner for byotrol24, and if the byotrol brand is established by then in the US then the risks of launching a new product would be correspondingly less.

The optionality built into the byotrol business by these licensing agreements is really starting to come into focus now.

[1gw] 23/1/2021 10:26

And looking through the Solvay jobs listing, here's the one for regulatory affairs for Actizone in the US. So this is the person that will handle EPA (FIFRA) registration for the products.

"The position is part of a highly interactive and supportive team and will manage product stewardship and registration activities relating to the Novecare business units innovations around Actizone disinfectant product lines."

"Manages the product registration program including planning, coordinating study programs with external labs, internal toxicologists and efficacy specialists."

"Maintains the FIFRA product registrations. Prepares and submits label and registration amendment applications when changes are required."

[1gw] 23/1/2021 10:15

If the earlier scientist healthcare role was open to interpretation about whether or not they were targeting N. America, this biz dev one is not. So Solvay is clearly going after at least some segments of the N. American market with Actizone, which I think is an expansion in scope compared to the finnCap assumption.

"Development of the ACTIZONE Healthcare business in North America in close cooperation with the ACTIZONE Management team based on a direct to market business model. The market space includes the nursing home market as well as the animal health market."

[1gw] 23/1/2021 10:04

Another 2 Solvay Actizone Biz Dev roles posted (presumably at same time as the Food one I noticed earlier), one for N America Heathcare and one for EMEA.

[1gw] 23/1/2021 09:43

Medirite is owned by Wightman & Parrish - see incorporation filing in 2012.

Medirite filed as a dormant company for 2019, so it looks like they have decided to reactivate it.

[riddlerone] 23/1/2021 09:26

May be small potatoes but here's a relatively new site that looks to have just started stocking Invirtu thats not actually on their website as a wholesaler.



Not a lot of info on them but the interesting thing is it looks like they have the same address as Wightman & Parrish a long established Healthcare supplier in the south east.

[riddlerone] 22/1/2021 19:12

All they need to do now is get the traffic through the sites which is obviously the hardest part.

[1gw] 22/1/2021 18:57

Heck, even the major shareholder page on the main corporate site was updated on 5th December. They must really feel they're starting to get on top of things if they're on to Aim Rule 26 compliance...

[click on Investor Overview / Shareholder Information]

[1gw] 22/1/2021 18:48

Medi-mark "where to buy" has also had a good upgrade.

[football] 22/1/2021 16:05

just look here to see what the troll STT is like




all the top bashing posts are voted up my himself to fill the MS up


and then bans anyone he doesn't like from posting on he's threads


doesn't like questions so bans everyone that asks

[sikhthetech] 22/1/2021 15:25

Another week gone and still no rns stating 'record orders' or "£1m per month'..

Looking at Boots

The sales have gone from around 100/day a year ago(Feb)
to 20-25 when last mentioned..


and recently has been even lower to around 15 bottles a day


50ml - 15 bottles sold in last 24 hrs.
200ml - 14 sold in last 24 hrs.
600ml - 12 sold in last 24



Global consumer sales were around £1m for H1-2021, during the spike in sales.
So looks like consumer sales level even lower..

[milesy] 22/1/2021 10:35

Now they've cleared the path to paying a divi (as and when appropriate) and, hopefully, with better visibility towards maintained and growing profitability, a PR push towards those fund managers who invest in AIM/Biotech stocks could bring about an expanded shareholder base.

[riddlerone] 22/1/2021 09:27

Considering the large percentage of the shareholder base that are private investors I do hope that DT decides to make another promotional video. As we saw last year it retains belief in the company and hence keeps the share price stable which is essential to form a base for when more contract/license news arrives.Also if we really are to capitalise on any potential acquisition this stability will again be imperative.I know I keep going on about it but its so important to keep shareholders on side and to give information on progress that does not constitute the need for an RNS/RNS reach.